| 08/11 | ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of E.. | GL |
| 08/08 | ALX ONCOLOGY : Reports Second Quarter 2022 Financial Results and Provides Clinical Develop.. | PU |
| 08/08 | ALX ONCOLOGY : Corporate Presentation | PU |
| 08/08 | ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition .. | AQ |
| 08/08 | ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo.. | GL |
| 08/08 | ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo.. | GL |
| 08/01 | ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm.. | GL |
| 08/01 | ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatm.. | GL |
| 06/29 | ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment.. | GL |
| 06/29 | ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment.. | AQ |
| 06/16 | ALX ONCOLOGY HOLDINGS INC : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
| 06/07 | ALX ONCOLOGY : Corporate Presentation | PU |
| 06/03 | ALX Oncology Announces Evorpacept Clinical Program Updates | GL |
| 06/03 | ALX Oncology Announces Evorpacept Clinical Program Updates | GL |
| 06/01 | ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference | GL |
| 05/09 | ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition .. | AQ |
| 05/09 | ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Develop.. | GL |
| 05/09 | ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Develop.. | AQ |
| 04/12 | ALX ONCOLOGY : Appoints Itziar Canamasas, Ph.D., to its Board of Directors - Form 8-K | PU |
| 04/12 | ALX ONCOLOGY HOLDINGS INC : Change in Directors or Principal Officers (form 8-K) | AQ |
| 04/12 | ALX Oncology Appoints Itziar Canamasas, Ph.D., to its Board of Directors | GL |
| 03/25 | ALX ONCOLOGY : Corporate Presentation | PU |
| 03/02 | ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept.. | GL |
| 02/28 | ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition .. | AQ |
| 02/28 | ALX ONCOLOGY : Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Cl.. | PU |
| 02/28 | ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides C.. | AQ |
| 01/27 | ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment.. | GL |
| 01/27 | ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment.. | GL |
| 01/18 | ALX ONCOLOGY : Corporate Presentation | PU |
| 01/10 | ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022 | GL |
| 01/10 | ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022 | GL |
| 01/04 | ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference | AQ |
| 2021 | ALX ONCOLOGY HOLDINGS INC : Entry into a Material Definitive Agreement, Financial Statemen.. | AQ |
| 2021 | DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Ind.. | PR |
| 2021 | ALX ONCOLOGY : ASH Conference Call Presentation | PU |
| 2021 | ALX ONCOLOGY : Corporate Presentation | PU |
| 2021 | ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evo.. | AQ |
| 2021 | ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition .. | AQ |
| 2021 | ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Develop.. | PU |
| 2021 | ALX Oncology Corporate Presentation | PU |
| 2021 | ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Develop.. | GL |
| 2021 | ALX Oncology SITC Conference Call Presentation | PU |
| 2021 | ALX Oncology Corporate Presentation, November 9, 2021 | PU |
| 2021 | ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpace.. | GL |
| 2021 | ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 6.. | GL |
| 2021 | ALX Oncology Announces Upcoming Virtual Investor Conference Participation | AQ |
| 2021 | ALX ONCOLOGY : Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept .. | GL |
| 2021 | ALX ONCOLOGY : Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio (Form 8-.. | PU |
| 2021 | ALX ONCOLOGY HOLDINGS INC : Unregistered Sale of Equity Securities, Other Events, Financia.. | AQ |
| 2021 | ALX ONCOLOGY : Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio | AQ |
| 2021 | ALX ONCOLOGY : Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clini.. | PU |
| 2021 | ALX ONCOLOGY : Corporate Presentation, October 5, 2021 | PU |
| 2021 | ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immu.. | GL |
| 2021 | ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148.. | GL |
| 2021 | ALX ONCOLOGY : Announces Upcoming Virtual Investor Conference Participation | AQ |
| 2021 | ALX ONCOLOGY HOLDINGS INC : Change in Directors or Principal Officers (form 8-K) | AQ |
| 2021 | ALX ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of .. | AQ |
| 2021 | ALX ONCOLOGY : Reports Second Quarter 2021 Financial Results and Provides Clinical Develop.. | PU |
| 2021 | ALX ONCOLOGY : Corporate Presentation, August 12, 2021 | PU |
| 2021 | ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Develo.. | GL |
| 2021 | ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Co.. | GL |
| 2021 | ALX ONCOLOGY : Corporate Presentation, July 16, 2021 | PU |
| 2021 | ALX ONCOLOGY : ESMO GI Presentation | PU |
| 2021 | ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Ro.. | GL |
| 2021 | ALX ONCOLOGY HOLDINGS INC : Submission of Matters to a Vote of Security Holders (form 8-K) | AQ |
| 2021 | ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Nec.. | GL |
| 2021 | ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), .. | GL |
| 2021 | ALX Oncology Announces Upcoming Virtual Investor Conference Participation | GL |
| 2021 | ALX ONCOLOGY : Reports First Quarter 2021 Financial Results and Provides Clinical Developm.. | PU |
| 2021 | ALX ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of .. | AQ |
| 2021 | ALX Oncology Reports First Quarter 2021 Financial Results and Provides Clinical Develop.. | GL |
| 2021 | ALX ONCOLOGY : Corporate Presentation, May 17, 2021 | PU |
| 2021 | ALX ONCOLOGY : NYAS Presentation | PU |
| 2021 | ALX ONCOLOGY : Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Com.. | AQ |
| 2021 | ALX ONCOLOGY HOLDINGS INC : Change in Directors or Principal Officers (form 8-K) | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
